Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy

Clinical Cancer Research

Volumn 9, Issue 2, 2003, Pages 802-811

  Bui, Matthew H T ^a   Seligson, David ^a   Han, Ken ryu ^a   Pantuck, Allan J ^a   Dorey, Frederick J ^a,b   Huang, Yunda ^a,b   Horvath, Steve ^a,b   Leibovich, Bradley C ^a   Chopra, Shefali ^a   Liao, Shu Yuan ^c   Stanbridge, Eric ^c   Lerman, Michael I ^d   Palotie, Aarno ^a   Figlin, Robert A ^a   Belldegrun, Arie S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; INTERLEUKIN 2; MOLECULAR MARKER; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STAINING;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; HUMANS; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; NEPHRECTOMY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0037314709     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer statistics, 2002. CA - Cancer J. Clin., 52: 23-47, 2002.
2. Figlin, R. A. Renal cell carcinoma: management of advanced disease. J. Urol., 161: 381-386; discussion 386-387, 1999.
3. Pantuck, A. J., Zisman, A., and Belldegrun, A. S. The changing natural history of renal cell carcinoma. J. Urol., 166: 1611-1623, 2001.
4. Bretheau, D., Lechevallier, E., de Fromont, M., Sault, M. C., Rampal, M., and Coulange, C. Prognostic value of nuclear grade of renal cell carcinoma. Cancer (Phila.), 76: 2543-2549, 1995.
5. Elson, P. J., Witte, R. S., and Trump, D. L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res., 48: 7310-7313, 1988.
6. Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., and Ferrara, J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol., 17: 2530-2540, 1999.
7. Bui, M. H., Zisman, A., Pantuck, A., Han, K., Wieder, J., and Belldegrun, A. Prognostic factors and molecular markers for renal cell carcinoma. Exp. Rev. Anticancer Ther., 1: 565-575, 2001.
8. Pastorek, J., Pastorekova, S., Callebaut, I., Mornon, J. P., Zelnik, V., Opavsky, R., Zat'ovicova, M., Liao, S., Portetelle, D., Stanbridge, E. J., et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene, 9: 2877-2888, 1994.
9. Wykoff, C. C., Pugh, C. W., Maxwell, P. H., Harris, A. L., and Ratcliffe, P. J. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene, 19: 6297-6305, 2000.
10. Ivanov, S., Liao, S. Y., Ivanova, A., Danilkovitch-Miagkova, A., Tarasova, N., Weirich, G., Merrill, M. J., Proescholdt, M. A., Oldfield, E. H., Lee, J., Zavada, J., Waheed, A., Sly, W., Lerman, M. I., and Stanbridge, E. J. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol., 158: 905-919, 2001.
11. Zavada, J., Zavadova, Z., Pastorekova, S., Ciampor, F., Pastorek, J., and Zelnik, V. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int. J. Cancer, 54: 268-274, 1993.
12. Oosterwijk, E., Ruiter, D., and Joedemaeker, P. Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney. Int. J. Cancer, 38: 489-494, 1986.
13. Murakami, Y., Kanda, K., Tsuji, M., Kanayama, H., and Kagawa, S. MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int., 83: 743-747, 1999.
14. Uemura, H., Nakagawa, Y., Yoshida, K., Saga, S., Yoshikawa, K., Hirao, Y., and Oosterwijk, E. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br. J. Cancer, 81: 741-746, 1999.
15. Liao, S. Y., Aurelio, O. N., Jan, K., Zavada, J., and Stanbridge, E. J. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res., 57: 2827-2831, 1997.
16. Steffens, M. G., Oosterwijk, W. J., Zegwaart, H. N., Boerman, O. C., Debruyne, F. M., Corstens, F. H., and Oosterwijk, E. Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250. Anticancer Res., 1197-1200, 1999.
17. Steffens, M. G., Boerman, O. C., Oosterwijk, W. J., Oosterhof, G. O., Witjes, J. A., Koenders, E. B., Oyen, W. J., Buijs, W. C., Debruyne, F. M., Corstens, F. H., and Oosterwijk, E. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J. Clin. Oncol., 15: 1529-1537, 1997.
18. Divgi, C. R., Bander, N. H., Scott, A. M., O'Donoghue, J. A., Sgouros, G., Welt, S., Finn, R. D., Morrissey, F., Capitelli, P., Williams, J. M., Deland, D., Nakhre, A., Oosterwijk, E., Gulec, S., Graham, M. C., Larson, S. M., and Old, L. J. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin. Cancer Res., 4: 2729-2739, 1998.
19. Steffens, M. G., Boerman, O. C., de, M. P., Oyen, W. J., Buijs, W. C., Witjes, J. A., van den, Broek, W. J., Oosterwijk, W. J., Debruyne, F. M., Corstens, F. H., and Oosterwijk, E. Phase 1 radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin. Cancer Res., 3268s-3274s, 1999.
20. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med., 4: 844-847, 1998.
21. Sobin, L. H., and Fleming, I. D. TNM Classification of Malignant Tumors, 5 Ed. (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer (Phila.), 80: 1803-1804, 1997.
22. Roila, F., Lupattelli, M., Sassi, M., Basurto, C., Bracarda, S., Picciafuoco, M., Boschetti, E., Milella, G., Ballatori, E., Tonato, M., et al. Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales. Ann. Oncol., 2: 437-439, 1991.
23. Fuhrman, S. A., Lasky, L. C., and Limas, C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am. J. Surg. Pathol., 6: 655-663, 1982.
24. Liao, S. Y., Brewer, C., Zavada, J., Pastorek, J., Pastorekova, S., Manetta, A., Berman, M. L., DiSaia, P. J., and Stanbridge, E. J. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am. J. Pathol., 145: 598-609, 1994.
25. Kaplan, E., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
26. Cox, D. R., and Oakes, D. Analysis of survival data. New York: Chapman and Hall, 1990.
27. Kalbfleisch, J. D., and Prentice, R. L. The statistical analysis of failure time data. New York: John Wiley, 1980.
28. Zisman, A., Pantuck, A. J., Dorey, F., Said, J. W., Shvarts, O., Quintana, D., Gitlitz, B. J., deKernion, J. B., Figlin, R. A., and Belldegrun, A. S. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol., 19: 1649-1657, 2001.
29. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 344: 783-792, 2001.
30. Vissers, J. L., De, V. I., Schreurs, M. W., Engelen, L. P., Oosterwijk, E., Figdor, C. G., and Adema, G. J. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res., 59: 5554-5559, 1999.
31. Uemura, H., Beniers, A. J., Okajima, E., Debruyne, F. M., and Oosterwijk, E. Vaccination with anti-idiotype antibodies mimicking a renal cell carcinoma-associated antigen induces tumor immunity. Int. J. Cancer, 58: 555-561, 1994.
32. Tso, C. L., Zisman, A., Pantuck, A., Calilliw, R., Hernandez, J. M., Paik, S., Nguyen, D., Gitlitz, B., Shintaku, P. I., de Kernion, J., Figlin, R., and Belldegrun, A. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res., 61: 7925-7933, 2001.
33. Parkkila, S., Rajaniemi, H., Parkkila, A. K., Kivela, J., Waheed, A., Pastorekova, S., Pastorek, J., and Sly, W. S. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc. Natl. Acad. Sci. USA, 97: 2220-2224, 2000.
34. Ivanov, S. V., Kuzmin, I., Wei, M. H., Pack, S., Geil, L., Johnson, B. E., Stanbridge, E. J., and Lerman, M. I. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl. Acad. Sci. USA, 95: 12596-12601, 1998.
35. Wykoff, C. C., Beasley, N. J., Watson, P. H., Turner, K. J., Pastorek, J., Sibtain, A., Wilson, G. D., Turley, H., Talks, K. L., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., and Harris, A. L. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res., 60: 7075-7083, 2000.
36. Olive, P. L., Aquino-Parsons, C., MacPhail, S. H., Liao, S. Y., Raleigh, J. A., Lerman, M. I., and Stanbridge, E. J. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res., 61: 8924-8929, 2001.
37. Shi, Q., Abbruzzese, J. L., Huang, S., Fidler, I. J., Xiong, Q., and Xie, K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin. Cancer Res., 5: 3711-3721, 1999.
38. Giatromanolaki, A., Koukourakis, M. I., Sivridis, E., Pastorek, J., Wykoff, C. C., Gatter, K. C., and Harris, A. L. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res., 61: 7962-7998, 2001.
39. Brewer, C. A., Liao, S. Y., Wilczynski, S. P., Pastorekova, S., Pastorek, J., Zavada, J., Kurosaki, T., Manetta, A., Berman, M. L., DiSaia, P. J., and Stanbridge, E. J. A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN. Gynecol. Oncol., 63: 337-344, 1996.
40. Saarnio, J., Parkkila, S., Parkkila, A. K., Haukipuro, K., Pastorekova, S., Pastorek, J., Kairaluoma, M. I., and Karttunen, T. J. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase. MN/CA IX, with potential value as a marker of cell proliferation. Am. J. Pathol., 153: 279-285, 1998.
41. Turner, J. R., Odze, R. D., Crum, C. P., and Resnick, M. B. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. Hum. Pathol., 28: 740-744, 1997.
42. Loncaster, J. A., Harris, A. L., Davidson, S. E., Logue, J. P., Hunter, R. D., Wycoff, C. C., Pastorek, J., Ratcliffe, P. J., Stratford, I. J., and West, C. M. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res., 61: 6394-6399, 2001.
43. Zhang, H., and Singer, B. Recursive partitioning in the health sciences, p. 238. New York: Springer-Verlag, 1999.
44. Rak, J., Yu, J. L., Kerbel, R. S., and Coomber, B. L. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res., 62: 1931-1934, 2002.
45. Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., Caton, J. R., Jr., Munshi, N., and Crawford, E. D. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med., 345: 1655-1659, 2001.